Company

Starpharma Holdings Limited

Headquarters: Abbotsford, VIC, Australia

Employees: 50

CEO: Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD

ASX: SPL +9.52%

Market Cap

A$72.1 Million

AUD as of Jan. 1, 2024

US$49.1 Million

Market Cap History

Starpharma Holdings Limited market capitalization over time

Evolution of Starpharma Holdings Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Starpharma Holdings Limited

Detailed Description

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Starpharma Holdings Limited has the following listings and related stock indices.


Stock: ASX: SPL wb_incandescent

Details

Headquarters:

4-6 Southampton Crescent

Abbotsford, VIC 3067

Australia

Phone: 61 3 8532 2700

Fax: 61 3 9510 5955